EcoDrugPlus

Phosphodiesterase 10a

Ensembl ID : ENSFHEG00000005830
Gene Symbol: PDE10A
3 Cross references
207 Possible Orthologues:

Phosphodiesterase 3a

Ensembl ID : ENSFHEG00000008361
Gene Symbol: PDE3A
2 Cross references
184 Possible Orthologues:

Phosphodiesterase 3b

Ensembl ID : ENSFHEG00000020441
Gene Symbol: PDE3B
3 Cross references
204 Possible Orthologues:

Phosphodiesterase 4a

Ensembl ID : ENSFHEG00000001663
Gene Symbol: PDE4A
3 Cross references
187 Possible Orthologues:

Phosphodiesterase 4b

Ensembl ID : ENSFHEG00000011126
Gene Symbol: PDE4B
3 Cross references
226 Possible Orthologues:

Phosphodiesterase 4d

Ensembl ID : ENSFHEG00000016937
Gene Symbol: PDE4D
3 Cross references
222 Possible Orthologues:

Phosphodiesterase 5a

Ensembl ID : ENSFHEG00000005298
Gene Symbol: PDE5A
4 Cross references
209 Possible Orthologues:

Phosphodiesterase 7a

Ensembl ID : ENSFHEG00000003632
Gene Symbol: PDE7A
3 Cross references
215 Possible Orthologues:

Phosphodiesterase 7b

Ensembl ID : ENSFHEG00000007951
Gene Symbol: PDE7B
4 Cross references
174 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 2

Ensembl ID : ENSFHEG00000006157
Gene Symbol: PIK3R2
3 Cross references
190 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSFHEG00000014966
Gene Symbol: PIK3R3
3 Cross references
199 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSFHEG00000009432
Gene Symbol: PIK3R3
3 Cross references
141 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).